• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Cutaquig (Immune Globulin Subcutaneous (Human) - hipp)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Cutaquig (Immune Globulin Subcutaneous (Human) - hipp)

  • Profile

Profile

Contact Information

Contact: Octapharma
Website: www.cutaquigus.com

Currently Enrolling Trials

    Show More

    General Information

    Cutaquig (Immune Globulin Subcutaneous (Human) - hipp) is a 16.5% immune globulin solution.

    Cutaquig is specifically indicated for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI).

    Cutaquig is supplied for subcutaneous infusion. 

    • Switching from Immune Globulin Intravenous (IGIV) to Cutaquig: calculate the dosing by using a dose conversion factor
    • Switching from other Immune Globulin Subcutaneous (IGSC): dosing should be the same as for previous IGSC.
    • Weekly : Start Cutaquig one week after last IGIV infusion Initial weekly dose = Previous IGIV dose (in grams) x 1.30 No. of weeks between IGIV doses
    • Every other week : Start Cutaquig 1 or 2 weeks after the last IGIV dosing or 1 week after the last IGSC administration. Infuse twice the calculated weekly dose.
    • More frequent than weekly (2-7 times a week): start Cutaquig 1 week after last IGIV or IGSC administration. Divide the calculated weekly dose by the desired number of infusions per week.

    Adjust dosing according to patient’s pharmacokinetics and clinical response.

    Mechanism of Action

    Cutaquig supplies a broad spectrum of opsonizing and neutralizing Immunoglobulin G (IgG) antibodies against a wide variety of bacterial and viral agents. It has a distribution of immune globulin subclasses closely proportional to that in native human plasma. The mechanism of action in primary humoral immunodeficiency (PI) has not been fully elucidated; however adequate doses may restore abnormally low immune globulin G levels to the normal range and thus help in preventing infections.

    Side Effects

    Adverse effects associated with Cutaquig may include, but are not limited to, the following:

    • local infusion site reactions
    • headache
    • fever
    • dermatitis
    • asthma
    • diarrhea
    • cough

    Clinical Trial Results

    The FDA approval of Cutaquig was based on the results of two clinical trials, which observed 75 PI patients, 37 adults and 38 pediatric patients between ages 2 and 17. The patients received weekly infusions with cutaquig during a 12-week wash-in/wash-out period followed by a 12-month efficacy period. The main objective of the research was to assess the efficacy of cutaquig in preventing serious bacterial infections, defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess. No serious bacterial infections were reported.

    Approval Date: 2021-12-01
    Company Name: Octapharma
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing